Authors' recommendations: After considering the strength of the available evidence in relation to the safety, clinical effectiveness and cost-effectiveness of radium-223 for the treatment of patients with symptomatic castrate resistant prostate cancer with skeletal metastases, MSAC supported public funding via a new MBS item. This support acknowledged the applicant's intention to negotiate a hidden arrangement to rebate the government in order to reflect a cost-effective price below the published fee. MSAC therefore advised that this price be recalculated based on the following modifications to the approach presented in the application: • the cost-utility analyses should use a lower threshold ICER ; and • the cost-minimisation analyses should use the effective price of cabazitaxel to the government rather than the price published in the Pharmaceutical Benefits Schedule.

Project Status: Completed

Year Published: 2014

URL for published report: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/1268-public

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Australia

Organisation Name: Medical Services Advisory Committee

Contact Address: MSAC (MDP 107), GPO Box 9848, Canberra, ACT 2601, Australia. Tel: +61 2 6289 6811; Fax: +61 2 6289 8799.

Contact Name: msac.secretariat@health.gov.au

Contact Email: msac.secretariat@health.gov.au

Copyright: Medical Services Advisory Committee (MSAC)